Terilyn J. Monroe - 12 Aug 2026 Form 4 Insider Report for Guardant Health, Inc. (GH)

Reporting relationship: Chief People Officer
Issuer ticker: GH
Reported as of: 12 Aug 2026
Net transaction value: -$7,645,218
SEC form: 4
Accepted by SEC: 13 Aug 2026, 19:21:04 UTC
Prior SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ John G. Saia, as attorney-in-fact for Terilyn J. Monroe

Key filing fact

Terilyn J. Monroe filed Form 4 for Guardant Health, Inc. (GH) on 13 Aug 2026.

Key facts

This page summarizes Terilyn J. Monroe's Form 4 filing for Guardant Health, Inc. (GH).
9 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 13 Aug 2026, 19:21.

Change

Previous filing in this sequence was filed on 02 Jul 2026.
Current net transaction value: -$7,645,218.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001652956 Primary reporting owner

Monroe Terilyn J.

Relationship: Chief People Officer
Address: 3100 HANOVER STREET, PALO ALTO
Signature: /s/ John G. Saia, as attorney-in-fact for Terilyn J. Monroe
Signature date: 13 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GH transaction

Common Stock

Options Exercise

Transaction value
Shares: +32,288
Change %: +141%
Price: $20.14^*
Shares after: 55,267
Date: 12 Aug 2026
Ownership: Direct

GH transaction

Common Stock

Options Exercise

Transaction value
Shares: +14,012
Change %: +25%
Price: $28.61^*
Shares after: 69,279
Date: 12 Aug 2026
Ownership: Direct

GH transaction

Common Stock

Sale

Transaction value: $605,286
Shares: -3,704
Change %: -5.3%
Price: $163.41
Shares after: 65,575
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F1

GH transaction

Common Stock

Sale

Transaction value: $1,631,870
Shares: -9,934
Change %: -15%
Price: $164.27
Shares after: 55,641
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F2

GH transaction

Common Stock

Sale

Transaction value: $3,140,310
Shares: -19,014
Change %: -34%
Price: $165.16
Shares after: 36,627
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F3

GH transaction

Common Stock

Sale

Transaction value: $2,200,584
Shares: -13,248
Change %: -36%
Price: $166.11
Shares after: 23,379
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F4

GH transaction

Common Stock

Sale

Transaction value: $67,168
Shares: -400
Change %: -1.7%
Price: $167.92
Shares after: 22,979
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GH transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -32,288
Change %: -75%
Price: $0.000000^*
Shares after: 10,916
Date: 12 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,288
Exercise price: $20.14
Footnotes: F6

GH transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -14,012
Change %: -43%
Price: $0.000000^*
Shares after: 18,615
Date: 12 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,012
Exercise price: $28.61
Footnotes: F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $162.80 to $163.78. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F2

Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.81 to $164.805. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F3

Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $164.825 to $165.82. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F4

Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $165.85 to $166.825. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F5

Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.695 to $168.02. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F6

This represents a stock option award granted on February 26, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 2, 2025 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.

Footnote F7

This represents a stock option award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.